Sky Labs스카이랩스

Sky Labs, listed on KOSDAQ in September 2026, has fallen about 39% in a month and trades far below its 52-week high.

Sky Labs makes wearable medical devices, including a cuffless blood pressure ring, and shares are at ₩11,780 against a 52-week range of ₩8,200 to ₩39,350. The company's annual and trailing financials, profit figures and valuation multiples are not available in the data, so its current financial position cannot be assessed from this pack. Recent filings are mostly 5%+ holding reports, insider shareholding reports and a major sales or supply contract.

What stands out

• Shares are down 39.4% over one month, with a market cap of about ₩221B, and 3-month and 1-year returns are not yet available since the stock has only recently listed.
• Foreign ownership rose from 1.6% to 3.7% over about 60 days, while institutions were net sellers over the last 20 days and retail and foreign investors were net buyers.
• A major sales or supply contract was filed on 2026-10-01, but its size and terms are not stated in the data.
• Financial statements, P/E, P/B and EV/EBITDA are not available for Sky Labs, so it cannot be compared with peers on valuation.
• Recent news focuses on the company's cuffless blood pressure technology and overseas sales, with one company claim that 7 in 10 patients reach target blood pressure.

What to watch

• Sky Labs' first annual or quarterly financial results as a listed company, which are not yet in the data.
• Further major contract filings and the size of overseas sales, which news says make up 52% of sales but which the data does not confirm.
• Continued 5%+ holding and insider shareholding reports, which may signal ownership changes after the recent price fall.